Old Web
English
Sign In
Acemap
>
authorDetail
>
Conn M. Harrington
Conn M. Harrington
Research Triangle Park
Cabotegravir
Medicine
Rilpivirine
long acting
Virology
3
Papers
5
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
2020
Open Forum Infectious Diseases
Ronald D' Amico
Paul Benn
Cynthia C McCoig
Sandy Griffith
Krischan J Hudson
Kenneth Sutton
Conn M. Harrington
Sterling Wu
Will Williams
Kai S Hove
Carlos Martín-Español
E Jane Fricker
Parul Patel
David A. Margolis
Show All
Source
Cite
Save
Citations (1)
1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome
2020
Open Forum Infectious Diseases
Christine L. Talarico
Sterling Wu
Ojesh R Upadhyay
Marty St. Clair
Veerle Van Eygen
Krischan J Hudson
Sandy Griffith
Conn M. Harrington
Jan van Lunzen
David A. Margolis
William Spreen
Show All
Source
Cite
Save
Citations (1)
884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
2019
Open Forum Infectious Diseases
Paula Teichner
Amy Cutrell
Ronald D' Amico
David Dorey
Sandy Griffith
Conn M. Harrington
Jenny Huang
Krischan J Hudson
David A. Margolis
Joseph Mrus
Joseph W. Polli
William Spreen
Peter Williams
Rodica Van Solingen-Ristea
Mark S. Shaefer
Show All
Source
Cite
Save
Citations (3)
1